AYTU vs. BNTC, MNOV, GNLX, ELDN, CKPT, VHAQ, AEON, SNGX, CNSP, and CELU
Should you be buying Aytu BioPharma stock or one of its competitors? The main competitors of Aytu BioPharma include Benitec Biopharma (BNTC), MediciNova (MNOV), Genelux (GNLX), Eledon Pharmaceuticals (ELDN), Checkpoint Therapeutics (CKPT), Viveon Health Acquisition (VHAQ), AEON Biopharma (AEON), Soligenix (SNGX), CNS Pharmaceuticals (CNSP), and Celularity (CELU). These companies are all part of the "pharmaceutical preparations" industry.
Aytu BioPharma (NASDAQ:AYTU) and Benitec Biopharma (NASDAQ:BNTC) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, dividends, risk, institutional ownership, media sentiment, valuation, profitability, community ranking and analyst recommendations.
Aytu BioPharma received 74 more outperform votes than Benitec Biopharma when rated by MarketBeat users. Likewise, 67.11% of users gave Aytu BioPharma an outperform vote while only 63.73% of users gave Benitec Biopharma an outperform vote.
In the previous week, Benitec Biopharma had 1 more articles in the media than Aytu BioPharma. MarketBeat recorded 1 mentions for Benitec Biopharma and 0 mentions for Aytu BioPharma. Benitec Biopharma's average media sentiment score of 0.59 beat Aytu BioPharma's score of 0.00 indicating that Benitec Biopharma is being referred to more favorably in the news media.
33.5% of Aytu BioPharma shares are held by institutional investors. Comparatively, 52.2% of Benitec Biopharma shares are held by institutional investors. 2.8% of Aytu BioPharma shares are held by company insiders. Comparatively, 4.3% of Benitec Biopharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Aytu BioPharma has higher revenue and earnings than Benitec Biopharma.
Aytu BioPharma presently has a consensus target price of $5.00, suggesting a potential upside of 65.02%. Benitec Biopharma has a consensus target price of $16.00, suggesting a potential upside of 115.63%. Given Benitec Biopharma's higher possible upside, analysts clearly believe Benitec Biopharma is more favorable than Aytu BioPharma.
Benitec Biopharma has a net margin of 0.00% compared to Aytu BioPharma's net margin of -14.60%. Aytu BioPharma's return on equity of -31.31% beat Benitec Biopharma's return on equity.
Aytu BioPharma has a beta of -1.31, indicating that its stock price is 231% less volatile than the S&P 500. Comparatively, Benitec Biopharma has a beta of 0.73, indicating that its stock price is 27% less volatile than the S&P 500.
Summary
Benitec Biopharma beats Aytu BioPharma on 8 of the 14 factors compared between the two stocks.
Get Aytu BioPharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for AYTU and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AYTU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aytu BioPharma Competitors List
Related Companies and Tools
